250 related articles for article (PubMed ID: 18090504)
21. Dose-response relationship of pregabalin in patients with generalized anxiety disorder. A pooled analysis of four placebo-controlled trials.
Bech P
Pharmacopsychiatry; 2007 Jul; 40(4):163-8. PubMed ID: 17694480
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China.
Guan Y; Ding X; Cheng Y; Fan D; Tan L; Wang Y; Zhao Z; Hong Z; Zhou D; Pan X; Chen S; Martin A; Tang H; Cui L
Clin Ther; 2011 Feb; 33(2):159-66. PubMed ID: 21444113
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study.
Pande AC; Feltner DE; Jefferson JW; Davidson JR; Pollack M; Stein MB; Lydiard RB; Futterer R; Robinson P; Slomkowski M; DuBoff E; Phelps M; Janney CA; Werth JL
J Clin Psychopharmacol; 2004 Apr; 24(2):141-9. PubMed ID: 15206660
[TBL] [Abstract][Full Text] [Related]
24. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial.
Kasper S; Herman B; Nivoli G; Van Ameringen M; Petralia A; Mandel FS; Baldinetti F; Bandelow B
Int Clin Psychopharmacol; 2009 Mar; 24(2):87-96. PubMed ID: 21456104
[TBL] [Abstract][Full Text] [Related]
26. Safety and efficacy of two pregabalin regimens for add-on treatment of partial epilepsy.
Beydoun A; Uthman BM; Kugler AR; Greiner MJ; Knapp LE; Garofalo EA;
Neurology; 2005 Feb; 64(3):475-80. PubMed ID: 15699378
[TBL] [Abstract][Full Text] [Related]
27. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in patients with generalized anxiety disorder: a prospective multicenter trial.
Cutler NR; Sramek JJ; Keppel Hesselink JM; Krol A; Roeschen J; Rickels K; Schweizer E
J Clin Psychopharmacol; 1993 Dec; 13(6):429-37. PubMed ID: 7907097
[TBL] [Abstract][Full Text] [Related]
28. Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial.
Bidzan L; Mahableshwarkar AR; Jacobsen P; Yan M; Sheehan DV
Eur Neuropsychopharmacol; 2012 Dec; 22(12):847-57. PubMed ID: 22898365
[TBL] [Abstract][Full Text] [Related]
29. Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety.
Owen RT
Drugs Today (Barc); 2007 Sep; 43(9):601-10. PubMed ID: 17940637
[TBL] [Abstract][Full Text] [Related]
30. Kava in the treatment of generalized anxiety disorder: a double-blind, randomized, placebo-controlled study.
Sarris J; Stough C; Bousman CA; Wahid ZT; Murray G; Teschke R; Savage KM; Dowell A; Ng C; Schweitzer I
J Clin Psychopharmacol; 2013 Oct; 33(5):643-8. PubMed ID: 23635869
[TBL] [Abstract][Full Text] [Related]
31. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
Davidson JR; Wittchen HU; Llorca PM; Erickson J; Detke M; Ball SG; Russell JM
Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
[TBL] [Abstract][Full Text] [Related]
32. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (GAD): single site findings from a multicenter trial.
Cutler NR; Sramek JJ; Wardle TS; Hesselink JM; Roeschen JK
Psychopharmacol Bull; 1993; 29(2):303-8. PubMed ID: 7904761
[TBL] [Abstract][Full Text] [Related]
33. Pregabalin: a novel gamma-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders.
Tassone DM; Boyce E; Guyer J; Nuzum D
Clin Ther; 2007 Jan; 29(1):26-48. PubMed ID: 17379045
[TBL] [Abstract][Full Text] [Related]
34. Pharmacotherapy of generalized anxiety disorder: focus and update on pregabalin.
Both C; Kojda G; Lange-Asschenfeldt C
Expert Rev Neurother; 2014 Jan; 14(1):29-38. PubMed ID: 24308277
[TBL] [Abstract][Full Text] [Related]
35. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial.
Gilron I; Wajsbrot D; Therrien F; Lemay J
Clin J Pain; 2011; 27(3):185-93. PubMed ID: 21178603
[TBL] [Abstract][Full Text] [Related]
36. Comparative efficacy of pregabalin and benzodiazepines in treating the psychic and somatic symptoms of generalized anxiety disorder.
Lydiard RB; Rickels K; Herman B; Feltner DE
Int J Neuropsychopharmacol; 2010 Mar; 13(2):229-41. PubMed ID: 19737439
[TBL] [Abstract][Full Text] [Related]
37. Pregabalin: dose-response relationship in generalized anxiety disorder.
Boschen MJ
Pharmacopsychiatry; 2012 Mar; 45(2):51-6. PubMed ID: 22086745
[TBL] [Abstract][Full Text] [Related]
38. Short-term tolerability of a nonazapirone selective serotonin 1A agonist in adults with generalized anxiety disorder: a 28-day, open-label study.
Mathew SJ; Garakani A; Reinhard JF; Oshana S; Donahue S
Clin Ther; 2008 Sep; 30(9):1658-66. PubMed ID: 18840371
[TBL] [Abstract][Full Text] [Related]
39. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies.
Pollack MH; Tiller J; Xie F; Trivedi MH
J Clin Psychopharmacol; 2008 Jun; 28(3):308-16. PubMed ID: 18480688
[TBL] [Abstract][Full Text] [Related]
40. An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia.
Pauer L; Winkelmann A; Arsenault P; Jespersen A; Whelan L; Atkinson G; Leon T; Zeiher B;
J Rheumatol; 2011 Dec; 38(12):2643-52. PubMed ID: 21965636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
